Methotrexate and misoprostol when surgical abortion fails

Area of Science:

• Reproductive Medicine
• Pharmacology
• Gynecology

Background:

• Suction curettage for early pregnancy termination can be challenging or impossible in cases of uterine or cervical anomalies.
• Alternative medical abortion methods are needed for patients with complex gynecological anatomy.

Purpose of the Study:

• To evaluate the efficacy and safety of methotrexate and misoprostol for inducing abortion in pregnancies up to 8 weeks.
• To describe the use of this medical regimen in patients with uterine or cervical anomalies contraindicating suction curettage.

Main Methods:

• A series of four women with pregnancies ≤8 weeks and failed suction curettage received intramuscular methotrexate (50 mg/m²) followed by vaginal misoprostol (800 µg).
• Repeat misoprostol doses were administered based on bleeding response and hCG levels.
• Follow-up included hCG assays, symptom logs, and satisfaction questionnaires.

Main Results:

• All four women with conditions including uterus bicornis bicollis, bicornuate uterus, leiomyomas, and cervical stenosis achieved complete abortion.
• Mild gastrointestinal side effects (nausea, vomiting, diarrhea) were reported by all subjects.
• All participants expressed satisfaction and would recommend the procedure over surgical abortion.

Conclusions:

• Methotrexate and misoprostol provide a successful medical abortion option for early pregnancies complicated by uterine or cervical anomalies.
• This regimen is a safe and effective alternative when suction curettage is contraindicated or has failed.